Fabrication, appraisal, and transdermal permeation of sildenafil citrate-loaded nanostructured lipid carriers versus solid lipid nanoparticles

Yosra SR Elnaggar¹
Magda A El-Massik²
Ossama Y Abdallah¹

¹Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, ²Department of Pharmaceutics, Faculty of Pharmacy and Drug Manufacturing, Pharos University, Alexandria, Egypt

Abstract: Although sildenafil citrate (SC) is used extensively for erectile dysfunction, oral delivery of SC encounters many obstacles. Furthermore, the physicochemical characteristics of this amphoteric drug are challenging for delivery system formulation and transdermal permeation. This article concerns the assessment of the potential of nanomedicine for improving SC delivery and transdermal permeation. SC-loaded nanostructured lipid carriers (NLCs) and solid lipid nanoparticles (SLNs) were fabricated using a modified high-shear homogenization technique. Nanoparticle optimization steps included particle size analysis, entrapment efficiency (EE) determination, freeze-drying and reconstitution, differential scanning calorimetry, in vitro release, stability study and high-performance liquid chromatography analysis. Transdermal permeation of the nanocarriers compared with SC suspension across human skin was assessed using a modified Franz diffusion cell assembly. Results revealed that SLNs and NLCs could be optimized in the nanometric range (180 and 100 nm, respectively) with excellent EE (96.7% and 97.5%, respectively). Nanoparticles have significantly enhanced in vitro release and transdermal permeation of SC compared with its suspensions. Furthermore, transdermal permeation of SC exhibited higher initial release from both SLN and NLC formulations followed by controlled release, with promising implications for faster onset and longer drug duration. Nanomedicines prepared exhibited excellent physical stability for the study period. Solid nanoparticles optimized in this study successfully improved SC characteristics, paving the way for an efficient topical Viagra® product.

Keywords: nanomedicine, transdermal drug delivery, erectile dysfunction, Viagra®

Introduction

Erectile dysfunction has been defined as the inability to attain and/or maintain a penile erection sufficient for satisfactory sexual performance. Although erectile dysfunction represents a major clinical problem, medical therapy for this condition was invasive or ineffective before the introduction of sildenafil citrate (SC).¹ SC is the first oral treatment to have had significant success in the treatment of erectile dysfunction. It acts via selective inhibition of the enzyme phosphodiesterase type 5. The physiologic mechanism of penile erection involves release of nitric oxide in the corpora cavernosa during sexual stimulation. This release activates the enzyme guanylate cyclase, relaxing the smooth muscle of the corpus cavernosum and allowing greater blood flow, thus leading to an erection.²⁻⁴ SC is an amphoteric drug with a pH-dependent solubility. The drug possesses a basic functional group (NH-piperazine), characterized by a pK value of 8.7, in addition to a weak acidic moiety (HN-amide), as shown in Figure 1.
SC is marketed as Viagra® oral tablets, with doses of 25, 50, and 100 mg taken not more than once a day.4

Unfortunately, oral administration of SC encounters numerous obstacles. The drug is vulnerable to considerable intestinal and hepatic first-pass metabolism (approximately 71% of oral dose).3 The drug is metabolized in the liver by the enzyme cytochrome P3A4, with an oral bioavailability of 40%. Furthermore, numerous side effects such as blood pressure reduction, headaches, flushing, and nasal congestion are concomitant with oral administration. Patients with moderate to severe cardiovascular disease or those undergoing nitrate therapy are at increased risk for potentially serious adverse cardiovascular side effects with SC therapy. In addition, relatively delayed onset (30–45 minutes) and short duration of action have been demonstrated for SC, with a half-life of 4 hours. In the meantime, repeated doses are required to sustain drug plasma levels.6,7

Transdermal delivery of SC through a local tissue area could be considered as an alternative to the oral route, in order to avoid these adverse side effects, to shorten onset time, and to sustain the effect for longer periods.8 In this context, nanosized colloidal carriers have been the subject of widespread interest in the field of transdermal drug delivery.8 Among these, solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) are attracting major attention as novel colloidal nanocarriers for topical use. Compared with liposomes and polymeric nanoparticles, SLNs exhibit the peculiarity of higher stability, capability of large-scale application, and avoidance of organic solvent incorporation.9,10 Compared with other topical vehicles such as creams, tinctures, and emulsions, combined advantages of SLNs include controlled release, negligible skin irritation, and protection of active compounds.7 Enhanced topical permeation via SLNs and NLCs is well recognized in the literature.11,12 Drugs that have exhibited improved transdermal penetration when incorporated into SLNs include flurbiprofen,13 ascorbyl palmitate,14 and ketorolac.15 On the other hand, NLCs are the second generation of SLNs incorporating a solid matrix that entraps variable lipid nanocompartments. NLCs have been shown to possess improved drug loading, adjusted drug release, and minimum drug expulsion during storage.16 NLCs remain in their solid state through controlling the liquid lipid content added to the formulation; therefore, controlled drug release properties can be achieved with NLCs.17 NLCs have also proved effective in the field of transdermal drug permeation.18

Nevertheless, a general challenge facing transdermal delivery of drugs is low skin permeation; reasons for this include the physicochemical properties of the compound, low partition ability, and formidable barrier properties of the stratum corneum. The majority of drugs do not appear to penetrate the skin at a sufficiently high rate to show therapeutic effectiveness. The feasibility of the transdermal route is thus limited to powerful actives presenting features such as appropriate low molecular weight and high lipophilicity.8 Further challenges in delivery-system formulation and transdermal permeation of SC are the amphoteric nature and pH-dependent characteristics of the compound. The drug possesses poor solubility in both aqueous and oil phases.4 Furthermore, in different pH environments, the drug will have different levels of ionization following the influence of the partition coefficient, as well as its permeation ability via the skin. Therefore, modification of the permeation parameters of SC has been reported as a major task in the development of an optimal drug for topical delivery formula; this includes improvement of onset time, maintenance of plasma level, and enhancement of skin permeation with subsequent lowering in dose and adverse effects.2,4 Yonessi and Saeedi9 investigated the effect of topical gel containing SC (1% SC in different cosolvents) compared with SC oral tablets on erectile dysfunction. They reported a significantly shorter onset of action and lower side effects for transdermal SC delivery. However, only 12.5% of patients had complete erection with transdermal SC delivery, compared with 70% of patients receiving oral therapy. Yonessi and Saeedi9 suggested that several percutaneous absorption enhancers could enhance transdermal SC delivery; this appears to be a promising approach for treatment of erectile dysfunction. However, no published trials on SC delivery systems and transdermal application have emerged so far.

Realizing the obstacles of SC oral delivery, the development of SC drug delivery systems for improving drug characteristics and therapy becomes a substantial undertaking. The aim of the study outlined in this article was
to improve SC delivery characteristics using nanocarriers. In a previous study, the present authors investigated self-nanoe-
mulsifying drug delivery systems and nanoemulsions for this purpose.19 In the current study, formulation and full in vitro appraisal of SC-loaded SLNs and NLCs were performed. The developed nanoparticles were designed in the previous study to fit both oral and topical application, whereas in the current investigation transdermal permeation of the prepared nanocarriers via human skin were assessed and compared with different drug suspensions. Furthermore, the physical shelf stability of both nanocarriers was assessed.

Materials and methods

Materials
SC was obtained from Sun Pharmaceutical Industries Ltd (Mumbai, India). Cetyl palmitate (CP) was obtained from Goldschmidt (Essen, Germany). Gattefossé (Lyon, France) kindly donated glycerol monolinoleate (Maisine™ 35-1 [M]). Polyoxyl 40 hydrogenated castor oil (Cremophor® RH 40 [CR]) was obtained from BASF (Ludwigshafen, Germany). Span™ 85 (hydrophilic-lipophilic balance (HLB) = 1.8) was obtained from Sigma-Aldrich (St Louis, MO). Propylene glycol and Tween 80 were obtained from Al-Nasr Pharmaceutical Chemicals Co (Cairo, Egypt). All other chemicals used were of analytical grade.

High-performance liquid chromatography
For this study, the authors utilized a previously validated high-performance liquid chromatography (HPLC) methodology20 with minor modifications, as outlined in the authors’ previous work.19 The HPLC instrument (Series 200; PerkinElmer Inc, Waltham, MA) was equipped with a reversed-phase C18 column (25 cm × 4.6 mm; particle size = 5 μm). The isocratic mobile phase, 20 mmol/L monopotassium phosphate (pH 4.7):acetonitrile (25:75), was run at a flow rate of 1.0 mL per minute at room temperature and the column effluent was monitored by an ultraviolet detector set at 293 nm. A 20 μL volume of each sample was automatically injected into the analytical column. Samples were injected concurrently within the standard solutions injections. The system was also equipped with a 600 Series Link Interface operated by TotalChrom chromatography data system software (v 6.2; PerkinElmer Inc, Waltham, MA). The calibration curve of peak area against SC concentration was Y = 862402.4 X –42324.3, under SC concentration of 0.5–9 mg%. Retention time was 4.3 plus or minus 0.3 minutes (R² = 0.9956; limit of quantification = 0.7 μg/mL; accuracy = 96.6%).

Preparation of SLNs and NLCs
As a consensus in the literature, high-pressure homogenization (HPH) is considered the optimum method for SLN formation. This is ascribed to exploitation of low surfactant content and avoidance of organic solvent incorporation.16 Nevertheless, HPH results in high particle surface energy and lower stability.17 In the current study, SLNs and NLCs were prepared using a modified high-shear homogenization method, in an attempt to combine the privileges of HPH while circumventing high-pressure implications. Two methods of drug loading, during and after carrier formation, were compared. In the first method, drug was dispersed in the surfactant/cosurfactant mixture (CR, Span 85, propylene glycol) using sonication (Julabo sonicator, USR-3; Julabo Labortechnik GmbH, Seelbach, Germany). Dispersion was aided by heating in the shaking water bath at 70°C for 5 minutes. Afterwards, the wax (CP) was added to the blend and melting was pursued for 20 minutes at 70°C. Water was heated separately to the same temperature and was then added to the component blend under high-shear homogenization at 3000 rpm, at 70°C for 5 minutes (T 25 digital Ultra-Turrax®; IKA, Staufen, Germany). The hot emulsion formed was poured into a fourfold volume of cold, distilled water under high-shear homogenization at 7000 rpm. Homogenization was pursued in a cold-water bath for 30 minutes. The nanoparticle dispersion formed was then filtered through a 0.8 μm membrane filter (diameter 25 mm; Micro Filtration Systems, Dublin, CA).

In the second method, solid lipid and surfactant blend were mixed and heated to 70°C for 20 minutes. Distilled water heated to the same temperature was then added under high-shear homogenization at 3000 rpm, at 70°C for 5 minutes. The hot emulsion formed was poured into a fourfold volume of cold, distilled water under high-shear homogenization at 7000 rpm. The placebo nanoparticles formed were then passed through a 0.8 μm membrane filter. After lipid nanoparticles were formed, drug was added quantitatively to SLN dispersion and sonicated for 15 minutes. As for NLCs, the liquid lipid (M) was mixed with the surfactant mixture. Dispersion was aided by heating in the shaking water bath at 70°C for 5 minutes. The same steps were then repeated for both methods (before and after carrier formation). For both SLNs and NLCs, two external phases (carbonate buffer [pH 10.3] and distilled water) were utilized and compared for their effect on nanoparticle characteristics. Composition of different SLN and NLC formulations is shown in Tables 1 and 2, respectively.
Average particle size was measured using a laser diffraction particle size analyzer (Cilas 1064; Cilas, Orléans, France). SLN and NLC dispersions were diluted with distilled water to concentrations of 0.25% and 7%, respectively. Samples were ultrasonicated for 3 minutes before measurement. Results were represented as mean particle size (duplicate) plus or minus standard deviation (SD).

Entrapment efficiency determination
The entrapment efficiency (EE) of the prepared SLNs and NLCs was assessed using Vivaspin ultracentrifuge tubes (Vivaspin® 6 Centrifugal Concentrator, molecular weight cutoff [MWCO] 100,000; Vivaproducts, Inc, Littleton, MA). Nanoparticle dispersion (3 mL) was added to the centrifuge tube and centrifugation was carried out for 15 minutes at 4000 rpm. The filtrate was diluted (1:3) with distilled water, and EE was determined as a percentage through the following equation:

$$EE\% = \frac{Mi - Mf}{Mi} \times 100$$

In this equation, Mi is the initial weight of SC and Mf is the weight of the free (unentrapped) drug detected in the filtrate. Samples were measured using the previously detailed HPLC method. Results were represented as the mean percentage (duplicate) plus or minus SD.

Freeze-drying and reconstitution
Nanoparticle dispersion (15 mL) was placed in 50 mL vials. Mannitol was added to the nanoparticle dispersion as a cryoprotectant in a final concentration of 4% (w/v). The vials were frozen at −80°C for 4 hours and were then placed in a lyophilizer (Cryodos-50; Telstar, SA, Terrassa, Spain) with a condenser temperature of −70°C. Lyophilization was performed at a pressure of 40 mbar and a shelf temperature of −40°C for 1 day, followed by a secondary drying at 25°C for another day. Lyophilized samples were kept at −80°C until used. Reconstitution was carried out by manual redispersion of lyophilized samples in 15 mL of distilled water. Samples were then suitably diluted with distilled water (1:100) and particle size was measured using the laser diffraction particle size analyzer. Sonication was carried out for 3 minutes before measurement.

Differential scanning calorimetry
Differential scanning calorimetry (DSC) was employed to study thermal behavior and detect polymorphism of SLNs compared with NLCs. DSC thermograms of selected samples were obtained using a differential scanning calorimeter (PerkinElmer, Rodgau, Germany). The selected samples were:

- CP heated to the same procedure temperature (70°C) as SLN and cooled suddenly in the same way (cold-water bath)
- physical mixture of CP and M (CP:M PH MIX) in formulation ratio (0.7:0.3), prepared in the same way as the CP sample
- physical mixture of CP, M, and CR (CP:M:CR PH MIX) in formulation ratio (0.7:0.3:1.3), prepared in the same way as the CP sample
- freeze-dried SLN (zero cryoprotectant)
- freeze-dried NLC (zero cryoprotectant)
- SC powder (as received).

Samples (10 mg) were weighed, hermetically sealed in an aluminum pan, and heated at a constant temperature increase rate of 5°C per minute over a temperature range of 20°C–200°C. The melting point, enthalpies, and onset temperature of the transition observed were reported.

### Table 1 Composition of sildenafil citrate (SC)-loaded solid lipid nanoparticle formulations (% w/v)*

<table>
<thead>
<tr>
<th>Formula</th>
<th>SC</th>
<th>CP</th>
<th>CR</th>
<th>Span™ 85</th>
<th>Carbonate buffer</th>
<th>Water</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xa</td>
<td>0.05</td>
<td>2</td>
<td>4</td>
<td>–</td>
<td>–</td>
<td>13</td>
</tr>
<tr>
<td>Xb</td>
<td>0.05</td>
<td>2</td>
<td>3</td>
<td>1</td>
<td>–</td>
<td>13</td>
</tr>
<tr>
<td>X1</td>
<td>0.05</td>
<td>2</td>
<td>2.6</td>
<td>1.4</td>
<td>–</td>
<td>13</td>
</tr>
<tr>
<td>X2</td>
<td>0.075</td>
<td>2</td>
<td>2.6</td>
<td>1.4</td>
<td>–</td>
<td>13</td>
</tr>
<tr>
<td>X3</td>
<td>0.1</td>
<td>2</td>
<td>2.6</td>
<td>1.4</td>
<td>–</td>
<td>13</td>
</tr>
<tr>
<td>X4</td>
<td>0.075</td>
<td>2</td>
<td>2.6</td>
<td>1.4</td>
<td>13</td>
<td>–</td>
</tr>
<tr>
<td>X5*</td>
<td>0.075</td>
<td>2</td>
<td>2.6</td>
<td>1.4</td>
<td>13</td>
<td>–</td>
</tr>
<tr>
<td>X6*</td>
<td>0.1</td>
<td>2</td>
<td>2.6</td>
<td>1.4</td>
<td>13</td>
<td>–</td>
</tr>
</tbody>
</table>

Notes: *All formulae contain 1% propylene glycol as cosurfactant; *drug added after carrier formation.

Abbreviations: CP, cetyl palmitate; CR, Cremophor® RH 40; M, Maisine™ 35-1.

### Table 2 Composition of sildenafil citrate (SC)-loaded nanostructured lipid carrier formulations (% w/v)*

<table>
<thead>
<tr>
<th>Formula</th>
<th>SC</th>
<th>CP</th>
<th>M</th>
<th>CR</th>
<th>Span™ 85</th>
<th>Carbonate buffer</th>
<th>Water</th>
</tr>
</thead>
<tbody>
<tr>
<td>N1</td>
<td>0.05</td>
<td>1.4</td>
<td>0.6</td>
<td>2.6</td>
<td>1.4</td>
<td>–</td>
<td>13</td>
</tr>
<tr>
<td>N2</td>
<td>0.075</td>
<td>1.4</td>
<td>0.6</td>
<td>2.6</td>
<td>1.4</td>
<td>–</td>
<td>13</td>
</tr>
<tr>
<td>N3</td>
<td>0.1</td>
<td>1</td>
<td>2.6</td>
<td>1.4</td>
<td>1.3</td>
<td>–</td>
<td>13</td>
</tr>
<tr>
<td>N4</td>
<td>0.075</td>
<td>1.4</td>
<td>0.6</td>
<td>2.6</td>
<td>1.4</td>
<td>13</td>
<td>–</td>
</tr>
<tr>
<td>N5*</td>
<td>0.075</td>
<td>1.4</td>
<td>0.6</td>
<td>2.6</td>
<td>1.4</td>
<td>13</td>
<td>–</td>
</tr>
<tr>
<td>N6*</td>
<td>0.1</td>
<td>1</td>
<td>2.6</td>
<td>1.4</td>
<td>1.3</td>
<td>13</td>
<td>–</td>
</tr>
</tbody>
</table>

Notes: *All formulae contain 1% propylene glycol as cosurfactant; *drug added after carrier formation.

Abbreviations: CP, cetyl palmitate; CR, Cremophor® RH 40; M, Maisine™ 35-1.
In vitro drug release
The in vitro drug release was assessed using the dialysis bag method. Drug release from optimum SLN formulation was compared with optimum NLC formulation, placebo nanoparticle dispersions, and drug suspension. SC was suspended in carbonate buffer (pH 10.3) (nanoparticle external phase) yielding suspension with the same drug strength of nanoparticles (0.1 g% w/v). Nanoparticle dispersions and drug suspension (7.5 mL) were added to the dialysis bag (Visking® 36/32, 27 mm, MWCO 12,000–14,000; Serva, Heidelberg, Germany). The bag was fixed to a 100 mL glass-stoppered container holding 50 mL of citrate buffer (pH 5). The experiment was carried out in a thermostated shaking water bath set at 37°C and 100 rpm. A placebo nanoparticle experiment was carried out concurrently. All samples were measured using HPLC analysis. All experiments were performed in triplicate. Results are presented as mean percentage of release plus or minus SD.

Transdermal permeation study
Skin collection and preparation
Intact, full-thickness human skin was obtained from arm plastic surgery. The subcutaneous fatty tissue was removed from the skin using a scalpel and surgical scissors. The skin surface was cleaned with Ringer’s solution and allowed to dry. Skin was completely covered by saline-immersed tissue, packed in aluminum foil, and stored in a polyethylene bag at −20°C. Human skin has been reported to be stable for 3–6 months under these conditions. All investigations were conducted in full compliance with the ethical principles of Mustafa El-Naggar Hospital (Semoha, Alexandria, Egypt).

Sample preparation and Franz diffusion cell assembly
Transdermal permeation of SC from the two nanocarriers developed was compared with that from drug suspensions in two nanocarrier external phases (carbonate buffer [pH 10.3] and water) using the same sample volume (0.75 mL) and final concentration (0.1%). The applied sample volume had considered unified amount of drug in all formulations (0.75 mg) to circumvent the concentration gradient effect on the rate of drug release.

Transdermal permeation of SC from the elaborated nanomedicines was assessed using a modified Franz diffusion cell assembly under nonocclusive conditions. The skin samples were mounted on modified Franz diffusion cells with a surface area of 3.14 cm² and a receptor volume of 8.5 mL. The skin was fixed so that the dermal side of the skin was exposed to the receptor fluid and the hypodermis remained in contact with the donor compartment. The receptor fluid consisted of citrate buffer solution (pH 5). After an equilibration time of 15 minutes at 32°C, formulations were applied in the donor compartment through direct contact to the skin. Diffusion cells were placed in a thermostatically controlled shaking water bath (type 3047; Köttermann, Hänigsen, Germany). Diffusion cells were shaken at 100 rpm, while the temperature was maintained at 32°C, simulating skin surface temperature. Sampling was performed at 0.5, 1.5, 5, and 24 hours. At each point, a 3 mL sample was withdrawn and replaced with fresh buffer. All experiments were carried out in triplicate. The HPLC method was used to measure the concentration of SC permeated in skin effluent samples.

Stability study
Stability study of selected SLN and NLC dispersions was carried out for 6 months. The nanodispersions were packed in well-sealed amber glass bottles at 4°C. Samples were taken each month and were analyzed for EE and particle size. In addition, nanodispersions were visually inspected for any physical instability (separation, aggregations, and so forth).

Statistical analysis
Statistical analysis of the results was carried out using Student’s t-test (P < 0.05).

Results and discussion
CP is a lipid wax used in SLN preparation and is also well recognized in topical application of SLNs. Eight SLNs prepared with CP have successfully enhanced the oral bioavailability of nitrendipine via lymphatic targeting. Furthermore, CP-based SLNs exhibited high physical stability compared with mono- and triglycerides. Preliminary studies investigated drug solubility in different system components. Different surfactants, cosurfactants, oily phases, and buffer systems were investigated. The ingredient that exhibited higher drug solubilization was picked up for nanoparticle formation. CR, propylene glycol, and M were chosen as the optimum surfactant, cosurfactant, and oily phase, respectively.

The influence of numerous factors on particle size and EE was investigated. Eight SLN formulations and six NLC formulations were prepared to study the effects of these factors on formula characteristics, as shown in Tables 1 and 2, respectively. Characterization of SLNs and NLCs was based on particle size analysis and EE assessment, as shown in Tables 3 and 4, respectively. The factors investigated included (1) ratio of CR to Span 85; (2) drug dosage influence; (3)
Abbreviation:

**Table 3** Characterization of sildenafil citrate (SC)-loaded solid lipid nanoparticles

<table>
<thead>
<tr>
<th>Formula</th>
<th>Mean particle size (μm)</th>
<th>SC entrapped (mg)</th>
<th>EE (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xa</td>
<td>1.13 ± 0.03</td>
<td>38.60 ± 1.13</td>
<td>96.50 ± 3.88</td>
</tr>
<tr>
<td>Xb</td>
<td>0.54 ± 0.01</td>
<td>35.15 ± 0.64</td>
<td>87.75 ± 1.59</td>
</tr>
<tr>
<td>X1</td>
<td>0.36 ± 0.02</td>
<td>36.10 ± 1.55</td>
<td>90.25 ± 3.88</td>
</tr>
<tr>
<td>X2</td>
<td>0.33 ± 0.07</td>
<td>46.55 ± 0.28</td>
<td>77.58 ± 0.47</td>
</tr>
<tr>
<td>X3</td>
<td>0.35 ± 0.14</td>
<td>46.76 ± 0.06</td>
<td>58.45 ± 0.07</td>
</tr>
<tr>
<td>X4</td>
<td>0.34 ± 0.40</td>
<td>50.79 ± 0.76</td>
<td>84.64 ± 1.26</td>
</tr>
<tr>
<td>X5</td>
<td>0.21 ± 0.60</td>
<td>73.02 ± 0.42</td>
<td>97.36 ± 0.56</td>
</tr>
<tr>
<td>X6</td>
<td>0.18 ± 0.15</td>
<td>96.65 ± 0.49</td>
<td>96.65 ± 0.49</td>
</tr>
</tbody>
</table>

Note: Data presented as mean ± standard deviation.
Abbreviation: EE, entrapment efficiency.

pH of the nanoparticle external phase; and (4) method of drug loading.

**Ratio of CR to Span 85**

An initial attempt of lipid nanoparticle preparation involved studying different ratios of CR (as oil-in-water emulsifier; HLB = 15) to Span 85 (as water-in-oil emulsifier; HLB = 1.8). Three ratios were compared: 100:0 (Xa), 75:25 (Xb), and 65:35 (X1). As Table 1 shows, the use of oil-in-water surfactant only (Xa) resulted in microparticles rather than nanoparticles. The addition of a water-in-oil emulsifier (Xb) resulted in a significant decrease in particle size (540 nm). Higher percentage of Span 85 (X1) resulted in further significant decrease in particle size (360 nm). This could be explained regarding the required HLB value for CP (HLB = 10). Realizing that the average HLB of CR is 15, large particle size of Xa (1.13 μm) could be justified. The HLB of the surfactant blend in Xb is 11.7 (Equation 2), while the HLB of the X1 surfactant blend is 10.4. The closeness of the X1 HLB to the required HLB of the lipid could explain its smaller particle size compared with Xb.

**Table 4** Characterization of sildenafil citrate (SC)-loaded nanostructured lipid carriers

<table>
<thead>
<tr>
<th>Formula</th>
<th>Mean particle size (μm)</th>
<th>SC entrapped (mg)</th>
<th>EE (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>N1</td>
<td>0.34 ± 0.22</td>
<td>37.39 ± 1.14</td>
<td>93.47 ± 2.83</td>
</tr>
<tr>
<td>N2</td>
<td>0.30 ± 0.14</td>
<td>47.62 ± 0.12</td>
<td>79.35 ± 0.20</td>
</tr>
<tr>
<td>N3</td>
<td>0.32 ± 0.13</td>
<td>48.80 ± 0.22</td>
<td>68.95 ± 3.37</td>
</tr>
<tr>
<td>N4</td>
<td>0.28 ± 0.05</td>
<td>58.35 ± 1.20</td>
<td>95.83 ± 2.00</td>
</tr>
<tr>
<td>N5</td>
<td>0.13 ± 0.03</td>
<td>73.80 ± 0.14</td>
<td>98.40 ± 1.13</td>
</tr>
<tr>
<td>N6</td>
<td>0.10 ± 0.21</td>
<td>97.50 ± 0.52</td>
<td>97.5 ± 0.52</td>
</tr>
</tbody>
</table>

Note: Data presented as mean ± standard deviation.
Abbreviation: EE, entrapment efficiency.

HLB (SAA blend) = HLB (CR) × % (CR) + HLB (Span 85) × % (Span 85) (2)

(SAA = surface active agent.) The elaborated surfactant blend ratio (65:35) was used for preparation and further optimization of SLNs and NLCs. The ratio of oil to solid lipid was fixed at 30:70 in all NLC formulations. This is the most common ratio in oil-loaded SLN formulations. No attempts to increase M ratio were adopted to avoid significant reduction in CP melting point, taking into consideration its original low melting point (43°C–53°C).

**Drug dosage influence**

In order to study the effect of increasing drug dose on formula characteristics, three SLN formulations (X1, X2, X3) (see Table 1) and three NLC formulations (N1, N2, N3) (see Table 2) were prepared. The formulae comprised three drug amounts (50, 75, and 100 mg% w/v) respectively. As Table 3 shows, the EE value of SLN formulae decreased significantly as the drug load increased. Increasing drug dose from 50 to 75 mg resulted in an increase in the entrapped weight in both SLNs and NLC. Nevertheless, by increasing the dose from 75 to 100 mg, the entrapped drug amount in SLN formulae was fixed to almost the same value (46.5 mg). This value is consistent with the sum drug solubility in all nanoparticle ingredients with their applied ratios. As for NLC formulations (Table 4), a slight increase in SC mg entrapped was noticed in N2 (47.62 mg) or N3 (48.80 mg) compared with their analogues X2 and X3, respectively. The drug amount exceeding solubility in ingredients is supposed to partition into the external phase (water), in which it is relatively more soluble than in solid lipid. The slight improvement could be ascribed to incorporation of M into the lipid matrix. As there was no significant improvement realized in EE through increasing the drug dose from 75 to 100 mg, the following factor effect was studied based on a SC dose of 75 mg (w/v).

**pH of the nanoparticle external phase**

In an attempt to increase the EE of drug-loaded SLN and NLC formulae, the use of a nanoparticle external phase with minimum drug affinity was investigated. The lowest drug affinity to the nanoparticle aqeous phase is supposed to permit higher drug accumulation inside lipid nanoparticles and on the shell. Therefore, drug solubility in different pH buffer systems was assessed. The buffers used were citrate buffer (pH 5), phosphate buffer (pH 7.4), and
carbonate buffer (pH 10.3). It was found that drug solubility decreased significantly as the pH increased. Drug solubility was lowest in carbonate buffer (0.05 mg/mL), followed by phosphate buffer (0.09 mg/mL), and was highest with citrate buffer (2.25 mg/mL). This could be explained by the basic functional group of the drug (NH-piperazine, pKa 8.7). The reverse relationship between sildenafil solubility and solvent pH is reported elsewhere. The buffer system 8.7). The reverse relationship between sildenafil solubility and solvent pH is reported elsewhere.4 The buffer system with the lowest drug solubilizing capacity (carbonate buffer, pH 10.3) was selected for the next preparations of SLN (X4) and NLC (N4). The prepared formulations were compared with their analogues prepared with water as external phase (X2 and N2, respectively). For SLNs (see Table 3), elevation of external phase pH resulted in an increase in the amount of drug entrapped: X4 had 50.79 mg; X2 had 46.5 mg. A more pronounced and significant increase was noticed in NLC formulation N4 (58.35 mg), prepared with carbonate buffer, compared with N2 (47.62 mg) (see Table 4). The enhanced improvement in EE of NLCs compared with SLNs could be explained by the fact that the solubility of active ingredients in oils is generally higher than in solid lipids. For this reason, the higher loading capacity could be achieved through the development of NLCs.6,24 It is worth noting that the pH of 10.3 was selected based on the literature investigating the topical and sublingual absorption of SC. Lia and Chang2 have reported that the transport amount of SC had the highest permeation rate in nude mouse skin, at pH 8–11. On the other hand, Wang et al7 have contended that a pH of 10.3 is optimum for sublingual permeation of SC. Therefore, the pH of 10.3 was selected as a compromise, to prepare nanoparticles that could be useful for both routes of administration. The alkaline buffer (pH 10.3) was selected as carbonate/bicarbonate constituents, while borax buffer was avoided. This was ascribed to the safety, regarding oral route, of the former buffer compared with the latter. Carbonate buffer was reported to be safe for both oral and topical application. The acute oral median lethal dose (LD50) for carbonate buffer in rats is 2.8 g/kg, while the dermal LD50 in rats is >3 g/kg. In addition, sodium carbonate has no or only a low skin irritation potential.27

**Method of drug loading**

The previous optimization steps have indicated optimum components, optimum formulation ratios, and optimum aqueous phase pH. For this step, SLNs (X4) and NLCs (N4) with high EE (84.64% and 95.83%, respectively) and reasonable particle size (340 and 280 nm, respectively) could be obtained. Nevertheless, although it combines many advantages, the high-shear homogenization method utilized in the study suffers from drug loss in the filtration step. This loss was confined to 20% plus or minus 1% of the labeled drug amount. In an attempt to decrease such loss, a different method of drug addition was assessed. The drug was alternatively loaded to nanoparticles after carrier formation and the filtration step, as explained earlier in the section on preparation of SLNs and NLCs. The SLN formulation X5 (Table 1) and the NLC formulation N5 (Table 2) were prepared exactly as X4 and N4, except that drug was added after the filtration step. The amount of SC incorporated was significantly increased when drug was added after carrier formation, for both SLNs and NLCs (Tables 3 and 4, respectively). Regarding SLNs, there was a significant increase in drug entrapped in X5 (73 mg) compared with X4 (50 mg). A significant increase was also noticed in the NLC formulation N5 (73.6 mg) compared with N4 (58.35 mg). To test the improved EE observed with the second method of addition, a higher SC dose (100 mg) was used in both SLNs (X6) and NLCs (N6). It was found that the amount of drug entrapped was also significantly enhanced in both cases. SLNs with 96.65 mg of SC entrapped and with a particle size of 180 nm could be prepared. Furthermore, the NLC formulation N6 with 97.5 mg of SC entrapped and a particle size of 100 nm could be prepared. For formulae X5, X6, N5, and N6 prepared via drug addition after carrier formation, a smaller globular size than others may be attributed to the additional sonication step.

**DSC**

In order to circumvent interfering peak of water, nanoparticle dispersions were subjected to DSC in the lyophilized form.16 Selected samples were thermally analyzed in an attempt to compare thermal characteristics of SLNs and NLCs. Results are demonstrated in Figure 2 and Table 5. CP revealed two peaks, a very minor peak at 32.4°C and a major peak at 47.12°C. Such a behavior of the solid lipid reflects two distinct polymorphic forms. From the literature reviews, the form with the lower melting point is attributed to α-polymorphic form, whereas the latter is attributed to the most stable β-polymorphic form. The melting point of CP in both SLNs (43.6°C) and NLCs (42.5°C) is lower than that of bulk material (45.6°C). While the melting point in NLCs was lower than SLNs by only one degree, the minor reduction in melting point reflects minor disturbance in the structure and crystallinity of CP through the addition of the
applied ratio of oil. This was supported by a comparison of the melting point of CP (45.6°C) with that of the lipid:oil physical mixture (44.5°C). These data explained and supported results of EE that demonstrated a minor difference in drug entrapped between SLNs and NLCs. This effect could be ascribed to the highly impacted crystalline structure of CP reported.\textsuperscript{26} It is worth noting that SC peak (190°C) did not appear in either SLN or NLC thermograms, owing to its very low percentage in the mixture (0.83%).

**In vitro release study**

In the process of biological permeation, the drug should first release from the vehicles, and then it can be partitioned into or absorbed by the skin or gastrointestinal tract.\textsuperscript{11}
As a consequence, assessment of in vitro drug release is a crucial step in paving the way for good permeation. The in vitro release of SC from the selected SLN (X6) and NLC (N6) formulations was assessed using the dialysis bag method. As demonstrated in Figure 3, the release from both SLN and NLC dispersions was significantly higher than from drug suspension under the same experimental conditions. On the other hand, drug release from NLC formulation N6 was significantly higher than SLN formulation X6. These results are consistent with those obtained by Fang et al., who reported higher drug flux from NLCs than SLNs across an artificial membrane. They proposed that incorporation of liquid lipids into the solid lipid matrix caused the NLCs to become more imperfect, with the implication of easier drug release. In addition, the lower globular size of NLCs (100 nm), compared with SLNs (180 nm), may also participate in higher drug release.

It is worth noting that the lower particle size of NLCs (100 nm) compared with SLNs (180 nm) has been reported elsewhere. This could indicate better emulsification of the solid lipid matrix when oil is incorporated in the solid matrix. These results agree with findings from the authors’ previous study where a nanoemulsion was prepared using M in the oil blend and the same surfactant mixture of nanoparticles. The nanoemulsion exhibited further decrease in particle size (70 nm) compared with oil-loaded SLNs (100 nm) and SLNs themselves (180 nm).

The optimization steps resulted in preparation of SC-loaded nanomedicines with promising in vitro characteristics. The ingredients utilized in SLN and NLC formulations are recognized for both oral and topical application. A future point of interest is the study of oral delivery of SC-loaded nanoparticles, considering incorporation of a bioactive surfactant-affecting cytochrome enzyme (CR), reported advantages of lipid nanoparticles in oral lymphatic targeting, and the capability of freeze-drying for preparation of nanocarriers as solid oral dosage form. In the current study, the transdermal permeation potential of the elaborated nanoparticles via human skin was assessed.

Transdermal permeation study

Excised human skin is properly regarded as the “gold standard” for in vitro penetration experiments related to human dermal risk assessment. Numerous animal skin models from various mammals and reptiles have been developed as surrogates for human skin. Nevertheless, animal skin tends to be more permeable than human skin. Consequently, full-thickness human skin was utilized in the current study.

In order to investigate the effect of external-phase pH, SC permeation levels from two different suspensions (carbonate buffer [pH 10.3] and water) were compared. As revealed in Figure 4, both suspensions exhibited low initial drug permeation (in the first 3 hours), which may be attributed to the formidable barrier of the stratum corneum. Subsequently, higher SC permeation was observed from the alkaline carbonate buffer than from the water suspension. This result is consistent with that obtained by Lia and Chang, who reported pH-dependent permeation of SC via nude mouse skin. On the other hand, drug permeation rates from both

Table 5 Peak onset, melting point, and enthalpy data of differential scanning calorimetry analysis

<table>
<thead>
<tr>
<th>Sample</th>
<th>Onset (°C)</th>
<th>Melting point (°C)</th>
<th>Enthalpy (J/g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CP: M: PH MIX (0.7:0.3)</td>
<td>34.46 ± 0.07</td>
<td>44.49 ± 0.09</td>
<td>107.50 ± 0.85</td>
</tr>
<tr>
<td>CP: M: PH MIX (0.7:0.3)</td>
<td>37.99 ± 0.06</td>
<td>44.92 ± 0.14</td>
<td>54.16 ± 0.17</td>
</tr>
<tr>
<td>SLNs</td>
<td>35.47 ± 0.33</td>
<td>43.59 ± 0.25</td>
<td>11.06 ± 0.16</td>
</tr>
<tr>
<td>NLCs</td>
<td>34.63 ± 0.15</td>
<td>42.47 ± 0.23</td>
<td>13.40 ± 0.12</td>
</tr>
<tr>
<td>SC</td>
<td>186.70 ± 0.49</td>
<td>190.75 ± 0.52</td>
<td>264.90 ± 0.63</td>
</tr>
</tbody>
</table>

Note: Data presented as mean ± standard deviation.

Abbreviations: CP, cetyl palmitate; CR, Cremophor® RH 40; M, Maisine™ 35-1; NLCs, nanostructured lipid carriers; PH MIX, physical mixture; SC, sildenafil citrate; SLNs, solid lipid nanoparticles.

Figure 3 In vitro release profiles of sildenafil citrate from nanostructured lipid carriers (NLCs), and solid lipid nanoparticles (SLNs) compared with drug suspension in carbonate buffer (pH 10.3) (citrate buffer, pH 5).

Figure 4 Transdermal permeation of sildenafil citrate (SC)-loaded nanoparticles across human skin versus drug suspensions in water and carbonate buffer (pH 10.3) (citrate buffer, pH 5).

Abbreviations: NLC, nanostructured lipid carrier; SLN, solid lipid nanoparticle.
nanocarriers were significantly higher than from both drug suspensions, with significantly higher initial SC permeation and subsequent sustained release.

In the field of transdermal drug delivery, small particle size is implicated as large surface area and film formation that consequently creates intimate drug contact with the corneocytes. In this way, the nanosize of NLCs (100 nm) and SLNs (180 nm) is expected to increase the amount of encapsulated drug penetrating into the viable skin. Furthermore, the occlusive effect of lipid nanodispersions increases hydration of the stratum, which by reducing corneocyte packing and widening of the intercorneocyte gaps can facilitate drug penetration via skin. Occlusive effects appear strongly related to particle size; therefore, nanoparticles were reported to be significantly more occlusive than microparticles. An additional mechanism of enhancement involves the fact that surfactants can loosen or fluidize the lipid bilayers of the stratum corneum and thus act as permeation enhancers. It is worth noting that both SLNs and NLCs exhibited almost the same initial permeation profile, whereas higher SC permeation from NLCs than from SLNs was observed after 5 hours of application. This could be attributed to lower particle size and better drug release from the particles as manifested in dialysis experiment.

**Stability study**

As a general consensus, waxes such as CP have been reported to exhibit higher physical stability than glycerides, owing to highly ordered crystal packing. In view of the current study, both nanoparticle dispersions were stored in closed bottles at 4°C in an attempt to investigate physical stability of SLNs and NLCs in liquid state. Particle size and EE data are shown in Table 6. Visual inspection revealed no aggregations or separation for SLNs or NLCs over the study period. Results revealed that both SLNs and NLCs kept their particle size, indicating good physical stability of the particles. In addition, EE values were also unchanged; this reflects avoidance of drug expulsion in the formulations elaborated for the period of the study. Results are consistent with those obtained by Jenning and Gohla, who reported high physical stability of CP, the wax utilized. In addition, avoidance of HPH is proposed to play a part in enhancing the stability of nanoparticles.

**Conclusion**

SC is a first-line treatment drug for erectile dysfunction. However, oral delivery of SC is hampered by various drawbacks including first-pass metabolism, numerous side effects, relatively short duration, and long onset of action. Furthermore, drug delivery formulation and transdermal application of SC is challenged by its amphoteric nature, low oil and water solubility, pH-dependent characteristics, and poor membrane permeability. In the current investigation, two different types of SC-loaded nanocarriers were optimized to improve drug characteristics and transdermal permeation. SC-loaded NLCs and SLNs could be elaborated to possess excellent EE and particle size. The optimized nanoparticles exhibited in vitro drug release superior to that of drug suspension. Elaborated NLCs had smaller particle size and higher drug release than SLNs. Both nanocarriers exhibited excellent stability for the study period. SLNs and NLCs exhibited enhanced transdermal permeation of SC via human skin, with higher initial release and controlled permeation profile than drug suspension alone. The NLCs elaborated in this study did not exhibit the usual significant superiority over SLNs in EE and stability. This was attributed to the highly ordered crystalline structure of CP, with minimum disruption of the structure upon addition of the small percentage of oily phase. Nanocarriers developed in this study have successfully improved SC transdermal permeation via human skin, with promising implications for shorter onset and longer duration of drug action. Furthermore, the formulated nanoparticles possess promising in vitro characteristics for oral and sublingual delivery, an area for future study.

**Disclosure**

The authors report no conflicts of interest in this work.

**Table 6** Stability study of sildenafil citrate-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs): selected formulations (X6, N6)

<table>
<thead>
<tr>
<th>Time (months)</th>
<th>SLN (X6)</th>
<th>NLC (N6)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Particle size (nm)</td>
<td>EE (%)</td>
</tr>
<tr>
<td>0</td>
<td>180 ± 0.15</td>
<td>96.65 ± 0.49</td>
</tr>
<tr>
<td>1</td>
<td>183 ± 0.23</td>
<td>96.70 ± 0.60</td>
</tr>
<tr>
<td>3</td>
<td>180 ± 0.18</td>
<td>96.30 ± 0.38</td>
</tr>
<tr>
<td>6</td>
<td>187 ± 0.42</td>
<td>96 ± 1.20</td>
</tr>
</tbody>
</table>

**Note:** Data presented as mean ± standard deviation. **Abbreviation:** EE, entrapment efficiency.

**References**


5. Shin HS, Bae SK, Lee MG. Pharmacokinetics of sildenafil after intravenous and oral administration in rats: hepatic and intestinal first-pass effects. Int J Pharm. 2006;320(1–2):64–70.


